Horizon Discovery Group plc (LSE:HZD) (“Horizon” or the “Company”), the world leader in the application of gene editing technologies, today announces that it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.
Intellia Therapeutics, a leading genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9 technology, has appointed Graeme Bell as its Chief Financial Officer.
CRISPR-Cas9 is revolutionizing gene engineering. And for those keen on the sector, there is ample opportunity to break into this market, thanks to the rise of CRISPR-based biotechs like Editas Medicine or Intellia Therapeutics. But before you buy in, read on. This emerging technology has plenty of potential—but also a
By Vivien Diniz
Editas Medicine’s share price went on a tear following its IPO in February. In the last two days, however, it’s dropped 36 percent. Here’s why.